The purchase comes as the "big 3" drug wholesalers are coming under scrutiny for their market dominance and the possible perils of vertical integration.
|Slideshows|July 31, 2020
- MHE July 2020
- Volume 30
- Issue 7
MHE 2020 Annual Pharmacy Survey pt. 3
Author(s)MHE Staff
Listen
0:00 / 0:00
As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. Third of three parts. See more in our Surveys tab.
Advertisement
Overall, the responses paint a picture of the pandemic having a major impact, which is not surprising, and reveal some optimism; for example, 78% of the respondents expect to see at least limited use of a COVID-19 vaccine by the first quarter of 2021.
Articles in this issue
about 6 years ago
Upping the Cardiovascular Health Gameabout 6 years ago
New Drugs Take Aim at Autoimmune Diseasesabout 6 years ago
Is the Biosimilars Waiting Game Finally Over?about 6 years ago
MHE 2020 Annual Pharmacy Survey pt. 2about 6 years ago
Racial Disparities in Cancer Enter the Spotlightabout 6 years ago
MHE 2020 Annual Pharmacy Surveyabout 6 years ago
Opinion: The Future of Pharmacy Care Services, Post-Pandemicabout 6 years ago
Has the C-Suite Gotten Too Big?about 6 years ago
Protecting the Integrity of EHR Clinical Decision Support ToolsAdvertisement
Related to this article
High prices and cutbacks in ACA and Medicaid coverage leave many patients unable to medical bills.
In this discussion, Heather Burrell-Ward, M.D., provides an overview of her recent study that found TMS aimed at the default mode network improved processing speed in schizophrenia.
Rand researchers identify standardizing supplemental benefits, limiting the number of plans an insurer can market and reforming broker commissions as policy proposals that would benefit beneficiaries while not harming the government or the plans.
Reimagine Care and Dan Nardi scale CAR-T programs with remote cancer care, AI triage and nurses, as the Cureety partnership tackles staffing and access.
Biosimilars can cost $600 a month versus $6,000 for branded rivals, but PBM rebate incentives push formularies toward pricier drugs, says Christine Johnston.
Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring.
In this interview, Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, discuss their study, which found a 16.8% increase in HIV incidence rates among Hispanic populations in antisanctuary counties after 2018 immigration policy shifts.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medical debt burdens more than 1 in 4 adults in the U.S., survey finds
2
Christine Johnston on why biosimilars are losing formulary ground
3
McKesson, private equity firm buy home infusion company, Option Care Health
4
A conversation with Heather Burrell Ward, M.D., about developing TMS as a treatment for the cognitive symptoms of schizophrenia
5